Despite the limitation of our model in which this synergistic effect required overexpression of MEF2C, these results point to the potential of SIK inhibitors in combination with steroid treatment for patients with ETP-ALL, who generally are more resilient toward steroid treatment. The gene discussed is SIK1; the disease is acute lymphoblastic leukemia.